NRG-CC007CD

Increasing the Dose of Survivorship Care Planning in Prostate Cancer Survivors Who Receive Androgen Deprivation Therapy

Principal Investigator

Ronald Chen, MD MPH

Status

Disease Site

Cancer Care Delivery Research [CD] Other

Phase

Other

Developmental Therapeutics

No

Primary Objective

To determine if the experimental arm (increased doses of SCP) has more patients who saw a primary care provider and had blood glucose and cholesterol checked in Year 2 (13-24 months) after finishing RT as compared to the control arm.

Patient Population

The participant must have a diagnosis of prostate adenocarcinoma that will be treated with RT plus ADT with curative intent.  Both definitive RT (intact prostate) and post-prostatectomy RT patients are eligible.  

Target Accrual

504